Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
March 22, 2023 06:45 ET
|
Pyxis Oncology
Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 First subject dosed in Phase 1 trial of PYX-201; clinical sites being activated and patient screening underway in Phase 1...
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
March 16, 2023 07:30 ET
|
Pyxis Oncology
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc....
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
February 13, 2023 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2022 16:45 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat...
Pyxis Oncology Announces FDA Clearance of Two IND Applications
December 01, 2022 06:45 ET
|
Pyxis Oncology
FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will...
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
November 01, 2022 06:30 ET
|
Pyxis Oncology
Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2022 17:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company focused on developing an arsenal of next-generation therapeutics to target...
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
August 15, 2022 07:00 ET
|
Pyxis Oncology
• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a senior biotech...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2022 06:45 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers,...
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
June 28, 2022 06:35 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today...